- Home
- RIGL vs PBPB Comparison
RIGL vs PBPB Comparison
Compare RIGL & PBPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- PBPB
- Stock Information
- Founded
- RIGL 1996
- PBPB 1977
- Country
- RIGL United States
- PBPB United States
- Employees
- RIGL N/A
- PBPB N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- PBPB Restaurants
- Sector
- RIGL Health Care
- PBPB Consumer Discretionary
- Exchange
- RIGL Nasdaq
- PBPB Nasdaq
- Market Cap
- RIGL 335.5M
- PBPB 305.0M
- IPO Year
- RIGL 2000
- PBPB 2013
- Fundamental
- Price
- RIGL $21.91
- PBPB $11.48
- Analyst Decision
- RIGL Buy
- PBPB Strong Buy
- Analyst Count
- RIGL 5
- PBPB 3
- Target Price
- RIGL $36.40
- PBPB $15.67
- AVG Volume (30 Days)
- RIGL 182.1K
- PBPB 235.6K
- Earning Date
- RIGL 08-05-2025
- PBPB 08-06-2025
- Dividend Yield
- RIGL N/A
- PBPB N/A
- EPS Growth
- RIGL N/A
- PBPB 1009.90
- EPS
- RIGL 2.08
- PBPB 1.39
- Revenue
- RIGL $203,077,000.00
- PBPB $465,126,000.00
- Revenue This Year
- RIGL $14.41
- PBPB $4.74
- Revenue Next Year
- RIGL $15.97
- PBPB $4.48
- P/E Ratio
- RIGL $10.11
- PBPB $8.25
- Revenue Growth
- RIGL 70.16
- PBPB N/A
- 52 Week Low
- RIGL $8.61
- PBPB $6.28
- 52 Week High
- RIGL $29.82
- PBPB $13.48
- Technical
- Relative Strength Index (RSI)
- RIGL 66.30
- PBPB 38.25
- Support Level
- RIGL $19.51
- PBPB $11.82
- Resistance Level
- RIGL $21.41
- PBPB $12.44
- Average True Range (ATR)
- RIGL 0.88
- PBPB 0.41
- MACD
- RIGL 0.24
- PBPB -0.18
- Stochastic Oscillator
- RIGL 96.45
- PBPB 9.50
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About PBPB Potbelly Corporation
Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.